Chemoprevention of cancer Robbins based md pathology exam answer
Reading File
Finding Sources
Finding Sources
Searching PubMed
cancer AND chemoprevention
Searching the Web
cancer chemoprevention National Cancer Institute prevention drugs tamoxifen aspirin
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Chemoprevention of Cancer
Definition:
Chemoprevention is the use of natural, synthetic, or biologic agents to prevent, reverse, or suppress carcinogenesis before invasive cancer develops. It is most useful in individuals with a defined high-risk state, precursor lesion, or inherited cancer syndrome.
Chemoprevention is the use of natural, synthetic, or biologic agents to prevent, reverse, or suppress carcinogenesis before invasive cancer develops. It is most useful in individuals with a defined high-risk state, precursor lesion, or inherited cancer syndrome.
Basis and objectives
Carcinogenesis is a multistep process consisting of:
- Initiation - irreversible DNA damage/mutation
- Promotion - clonal expansion of initiated cells
- Progression - acquisition of malignant phenotype
Chemopreventive agents act by blocking one or more of these stages. The ideal agent should be safe for long-term use, affordable, and directed toward a known molecular pathway in a high-risk population.
Mechanisms of chemoprevention
| Stage targeted | Main mechanism | Examples |
|---|---|---|
| Anti-initiation | Inhibit activation of procarcinogens, enhance detoxification, scavenge reactive oxygen species, or prevent DNA damage | Isothiocyanates, some plant polyphenols |
| Anti-promotion | Reduce chronic inflammation, proliferation, and prostaglandin-mediated growth signals | Aspirin, NSAIDs, COX-2 inhibitors |
| Anti-progression / differentiation | Block hormone-dependent growth, induce differentiation or apoptosis | Tamoxifen, raloxifene, retinoids |
| Targeted prevention | Inhibit a molecular driver associated with high cancer risk | 5-alpha reductase inhibitors in selected prostate-risk settings |
Important examples
1. Colorectal carcinoma
- Aspirin and other NSAIDs have a protective effect against colorectal neoplasia.
- They can cause regression of adenomatous polyps in familial adenomatous polyposis (FAP).
- The proposed mechanism is inhibition of COX-2, which is overexpressed in many colorectal adenomas and carcinomas. COX-2 produces prostaglandin E2, promoting epithelial proliferation.
- Selective COX-2 inhibitors such as celecoxib can reduce adenoma formation but long-term use is limited by cardiovascular toxicity.
Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 758.
2. Breast carcinoma
- Tamoxifen and raloxifene are selective estrogen receptor modulators that lower the risk of ER-positive breast cancer in women at high risk.
- They are considered in selected women with strong family history, atypical hyperplasia, LCIS, or hereditary susceptibility, after balancing risks and benefits.
- Tamoxifen has adverse effects including thromboembolism and increased endometrial carcinoma risk; raloxifene is used in postmenopausal women.
Robbins states that ER antagonists reduce the incidence of ER-positive cancers and are mainly used in women at very high risk, including carriers of germline BRCA1/BRCA2 mutations. Robbins, Cotran & Kumar Pathologic Basis of Disease.
3. Head and neck cancers
- Retinoids have been studied to induce differentiation and suppress epithelial carcinogenesis, particularly in high-risk premalignant lesions.
- Their widespread long-term use is restricted by toxicity and inconsistent benefit in many settings.
4. Prostate cancer
- 5-alpha reductase inhibitors, such as finasteride and dutasteride, reduce conversion of testosterone to dihydrotestosterone and have been studied for risk reduction.
- Their role remains selective because prevention of clinically meaningful cancer must be weighed against adverse effects and concerns related to detection of high-grade tumors.
Dietary and antioxidant agents
Dietary phytochemicals, antioxidants, vitamins, and micronutrients have been investigated because of their possible antioxidant and anticarcinogenic actions. However:
- Epidemiologic associations do not necessarily establish preventive benefit.
- Randomized trials have often failed to show benefit.
- Some agents may be harmful. For example, alpha-tocopherol was associated with increased prostate cancer risk in a major trial.
- Therefore, vitamin or antioxidant supplements should not be routinely prescribed solely for cancer prevention.
Robbins, Cotran & Kumar Pathologic Basis of Disease notes that there is no convincing evidence that antioxidants act as effective chemopreventive agents.
Limitations
- Many healthy or asymptomatic people must be treated to prevent relatively few cancers.
- Long-term toxicity is important: gastrointestinal bleeding with NSAIDs, cardiovascular events with COX-2 inhibitors, thromboembolism/endometrial cancer with tamoxifen.
- Benefit is usually limited to particular cancer types and high-risk groups.
- Chemoprevention does not replace elimination of carcinogenic exposures, vaccination, screening, and treatment of precursor lesions.
Conclusion
Chemoprevention is a rational approach to cancer prevention that targets the molecular events of initiation, promotion, and progression. Its best-established applications are aspirin/NSAIDs in colorectal neoplasia and anti-estrogen therapy for high-risk ER-positive breast cancer. It should be used selectively in high-risk individuals after assessing adverse effects.
For context, the NCI definition similarly describes chemoprevention as use of drugs or other substances to lower cancer risk or prevent recurrence. Recent evidence is still evolving, including a 2025 systematic review of gastrointestinal cancer chemoprevention (PMID: 40344467).
This is a shared conversation. Sign in to Orris to start your own chat.